Navigation Links
Resverlogix Presents Key Apo-Al/HDL Scientific Data at DALM
Date:10/4/2007

TSX Exchange Symbol: RVX

CALGARY, Oct. 4 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) is pleased to announce today that the Company is making an oral presentation of key scientific data of its lead clinical candidate, RVX-208, at the 16th International Symposium for Drugs Affecting Lipid Metabolism (DALM). The presentation titled, "A novel drug RVX-208 raises plasma apolipoprotein A-l and HDL cholesterol", will be presented by Dr. Norman Wong on October 4, 2007 at the Hilton Hotel in New York City.

"DALM is a premier international conference renowned for its content of state of the art therapeutics for the prevention of atherosclerosis and other cardiovascular diseases. We are pleased that Resverlogix will present its data detailing RVX-208, a small molecule drug which enhances the production of ApoA-l and HDL," stated Dr. Jan Johansson, Senior Vice President of Clinical Affairs of Resverlogix. Dr. Johansson added, "The scientific community recognizes the importance of a small molecule in the form of an oral tablet that significantly increases ApoA-I production, thereby enhancing the function of HDL. These beneficial effects of RVX-208 will potentially reduce the risk of atherosclerosis and cardiovascular disease."

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet needs. The NexVas(TM) program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-l. These vital therapies address the grievous burden of atherosclerosis and other important diseases such as acute coronary syndrome, diabetes, Alzheimer's and other vascular disorders. The Company's secondary focus is TGF-Beta Shield(TM), a program that aims to address burgeoning grievous diseases, such as cancer and fibrosis. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX). For further information please visit http://www.resverlogix.com.

This news release may contain certain forward-looking statements that reflect the current views and/or expectations of Resverlogix Corp. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.

Note to editors: Ken Lebioda, Senior Vice-President, will be attending the conference and can meet in person with interested media.


'/>"/>
SOURCE Resverlogix Corp.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. NimbleGen presents new tech for comparing microbe DNA
2. Wisconsin Technology Network presents symposium on saving lives by the use of Information Technology
3. Thieme Presents Unique Technology Angle at Gov.s Conference
4. UW-Madisons Beebe wins scientific award
5. Researchers say scientific reporting needs more perspective, less hype
6. Wisconsin stands at the center of scientific efforts to avert flu epidemics
7. Growth prompts new location for scientific instrument manufacturer
8. UW stem cell guru outlines scientific and political future
9. Wisconsin biotech sector featured in scientific magazine
10. Scientific Protein Laboratories Acquired by New York firm
11. GenTel Appoints Burke to its Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... is pleased to announce the launch of their brand, UP4™ Probiotics, into Target ... over 35 years, is proud to add Target to its list of well-respected ...
(Date:6/23/2016)... , June 23, 2016 A person commits ... the crime scene to track the criminal down. ... U.S. Food and Drug Administration (FDA) uses DNA evidence to ... Sound far-fetched? It,s not. The FDA has ... to support investigations of foodborne illnesses. Put as simply as ...
(Date:6/23/2016)... , June 23, 2016  The Prostate Cancer Foundation (PCF) is ... treatments and faster cures for prostate cancer. Members of the Class of 2016 ... countries. Read More About the Class of 2016 PCF ... ... ...
Breaking Biology Technology:
(Date:6/27/2016)... Research and Markets has announced the addition of the "Biometrics ... The report forecasts the biometrics market ... CAGR of 12.28% during the period 2016-2020. The ... inputs from industry experts. The report covers the market landscape and ... a discussion of the key vendors operating in this market. ...
(Date:6/22/2016)... Md. , June 22, 2016  The American College ... Trade Show Executive Magazine as one of the ... on May 25-27 at the Bellagio in Las ... on the highest percentage of growth in each of the ... of exhibiting companies and number of attendees. The 2015 ACMG ...
(Date:6/22/2016)... ANGELES , June 22, 2016 /PRNewswire/ ... identity management and verification solutions, has partnered ... edge software solutions for Visitor Management, Self-Service ... provides products that add functional enhancements ... partnership provides corporations and venues with an ...
Breaking Biology News(10 mins):